Mark Neumann Intra Cellular Therapies, Inc. (ITCI) insider trading activity

Mark Neumann is EVP, Chief Commercial Officer of Intra-Cellular Therapies, Inc.. Currently has a direct ownership of 52,811 shares of ITCI, which is worth approximately $6.94 Million. The most recent transaction as insider was on Mar 10, 2025, when has been sold 3,116 shares (Common Stock) at a price of $131.24 per share, resulting in proceeds of $408,943. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 52.8K

77.81% 3M change

77.81% 12M change

Total Value Held $6.94 Million

Mark Neumann Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 10 2025	SELL Payment of exercise price or tax liability	$408,943 $131.24 p/Share	3,116 Reduced 5.57%	52,811 Common Stock
Mar 10 2025	BUY Exercise of conversion of derivative security	-	7,345 Added 11.61%	55,927 Common Stock
Mar 06 2025	SELL Payment of exercise price or tax liability	$730,990 $131.19 p/Share	5,572 Reduced 10.29%	48,582 Common Stock
Mar 06 2025	BUY Exercise of conversion of derivative security	-	13,133 Added 19.52%	54,154 Common Stock
Mar 01 2025	SELL Payment of exercise price or tax liability	$475,493 $128.2 p/Share	3,709 Reduced 8.29%	41,021 Common Stock
Mar 01 2025	BUY Exercise of conversion of derivative security	-	8,742 Added 16.35%	44,730 Common Stock
Jan 31 2025	SELL Payment of exercise price or tax liability	$600,583 $127.0 p/Share	4,729 Reduced 11.61%	35,988 Common Stock
Jan 31 2025	BUY Grant, award, or other acquisition	-	11,017 Added 21.3%	40,717 Common Stock
Aug 16 2024	SELL Open market or private sale	$1,405,047 $75.08 p/Share	18,714 Reduced 38.65%	29,700 Common Stock
Aug 16 2024	BUY Exercise of conversion of derivative security	$690,359 $36.89 p/Share	18,714 Added 27.88%	48,414 Common Stock
Mar 11 2024	SELL Open market or private sale	$484,476 $65.96 p/Share	7,345 Reduced 19.83%	29,700 Common Stock
Mar 10 2024	BUY Exercise of conversion of derivative security	-	7,345 Added 16.55%	37,045 Common Stock
Mar 07 2024	SELL Open market or private sale	$875,379 $66.66 p/Share	13,132 Reduced 30.66%	29,700 Common Stock
Mar 06 2024	BUY Exercise of conversion of derivative security	-	13,132 Added 23.47%	42,832 Common Stock
Feb 26 2024	SELL Open market or private sale	$552,462 $69.87 p/Share	7,907 Reduced 21.03%	29,700 Common Stock
Feb 23 2024	BUY Exercise of conversion of derivative security	-	7,907 Added 17.37%	37,607 Common Stock
Feb 02 2024	SELL Open market or private sale	$795,568 $67.08 p/Share	11,860 Reduced 28.54%	29,700 Common Stock
Feb 01 2024	BUY Grant, award, or other acquisition	-	11,860 Added 22.2%	41,560 Common Stock
Nov 06 2023	SELL Open market or private sale	$2,352,811 $55.5 p/Share	42,393 Reduced 58.8%	29,700 Common Stock
Nov 06 2023	BUY Exercise of conversion of derivative security	$640,490 $23.94 p/Share	26,754 Added 27.07%	72,093 Common Stock
Aug 07 2023	SELL Open market or private sale	$3,251,087 $58.79 p/Share	55,300 Reduced 54.95%	45,339 Common Stock
Aug 07 2023	BUY Exercise of conversion of derivative security	$1,028,027 $18.59 p/Share	55,300 Added 35.46%	100,639 Common Stock
Mar 28 2023	SELL Open market or private sale	$849,325 $54.43 p/Share	15,604 Reduced 25.6%	45,339 Common Stock
Mar 13 2023	SELL Open market or private sale	$167,494 $44.57 p/Share	3,758 Reduced 5.81%	60,943 Common Stock
Mar 10 2023	SELL Open market or private sale	$368,676 $43.12 p/Share	8,550 Reduced 12.97%	57,357 Common Stock

Mark Neumann

EVP, Chief Commercial Officer

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITCI shares.

Notify only if

Value

Insider Trading

Get notified when an Intra Cellular Therapies, Inc. insider buys or sells ITCI shares.

Notify only if

Operation

Value

Type

News

Receive news related to Intra-Cellular Therapies, Inc.

Track Activities on ITCI

Account